C4 Therapeutics Inc.

NASDAQ: CCCC · Real-Time Price · USD
2.46
0.11 (4.68%)
At close: Aug 15, 2025, 3:59 PM
2.46
0.20%
After-hours: Aug 15, 2025, 06:51 PM EDT

C4 Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Revenue
n/a 7.24M 5.18M 15.36M 12.01M 3.04M 3.26M 11.07M 2.66M 3.76M 2.85M 6.75M 13.83M 7.65M 20.08M 8.5M 9.78M
Cost of Revenue
n/a n/a 1.77M 2.06M 2.04M 2.03M 1.69M 2M 1.99M 2.06M 2.02M 1.92M 2.14M 1.49M 758K 24.3M 23.29M
Gross Profit
n/a 7.24M 3.41M 13.31M 9.96M 1.01M 1.57M 9.08M 675K 1.7M 831K 4.83M 11.69M 6.17M 19.32M -15.8M -13.51M
Operating Income
-28.5M -29.16M -37.71M -28.24M -21.44M -32.22M -37.43M -27.81M -37.57M -36.23M -38.29M -32.49M -27.38M -31.37M -15.26M -24.25M -22.12M
Interest Income
n/a 2.84M 3.27M 3.58M 3.73M 3.86M 2.95M 2.56M 2.25M 2.05M 1.71M 1.08M 506K 276K 136K 110K 69K
Pretax Income
-26.02M -26.32M -34.44M -24.67M -17.72M -28.36M -34.48M -26.03M -35.92M -34.78M -37.19M -31.96M -27.41M -31.62M -15.66M -24.68M -22.58M
Net Income
-26.02M -26.32M -34.57M -24.67M -17.72M -28.36M -34.75M -27.04M -35.92M -33.94M -36.08M -31.43M -27.44M -31.87M -15.66M -24.68M -22.58M
Selling & General & Admin
8.77M 9.33M 10.37M 11.77M 9.7M 10.29M 8.61M 10.53M 10.31M 10.95M 10.49M 9.58M 9.89M 12.82M 8.78M 8.45M 8.61M
Research & Development
26.2M 27.07M 32.51M 31.84M 23.75M 22.53M 30.39M 28.35M 29.93M 29.04M 30.65M 29.66M 31.32M 26.2M 26.55M 24.3M 23.29M
Other Expenses
n/a n/a n/a n/a n/a 2.44M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
34.96M 36.4M 41.12M 43.61M 33.45M 35.26M 39M 38.88M 40.23M 39.99M 41.15M 39.24M 41.22M 39.02M 35.33M 32.75M 31.9M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a 167K 600K 606K 601K 554K 534K 527K 539K 539K 533K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -1.69M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 36.4M 42.89M 43.61M 33.45M 35.26M 40.69M 38.88M 40.23M 39.99M 41.15M 39.24M 41.22M 39.02M 35.33M 32.75M 31.9M
Income Tax Expense
n/a n/a 131K n/a n/a -2.03M 277K -1M n/a -842K -1.11M -530K 28K 251K n/a 110K 69K
Shares Outstanding (Basic)
71.01M 70.83M 70.61M 69.63M 68.81M 68.43M 51.22M 49.21M 49.06M 49.03M 48.97M 48.92M 48.82M 48.65M 48.49M 48.49M 43.86M
Shares Outstanding (Diluted)
71.01M 70.83M 70.61M 69.63M 68.81M 68.43M 51.22M 49.21M 49.06M 49.03M 48.97M 48.92M 48.82M 48.73M 48.49M 48.49M 43.86M
EPS (Basic)
-0.37 -0.37 -0.49 -0.35 -0.26 -0.41 -0.68 -0.55 -0.73 -0.69 -0.74 -0.64 -0.56 -0.66 -0.32 -0.51 -0.51
EPS (Diluted)
-0.37 -0.37 -0.49 -0.35 -0.26 -0.41 -0.68 -0.55 -0.73 -0.69 -0.74 -0.64 -0.56 -0.65 -0.32 -0.51 -0.51
EBITDA
-28.5M -28.71M -32.68M -22.61M -15.67M -26.33M -32.79M -23.87M -33.33M -32.11M -34.56M -29.48M -24.74M -29.6M -14.36M -23.81M -21.33M
EBIT
n/a -29.16M -34.44M -24.67M -17.72M -28.36M -34.48M -25.87M -35.32M -34.17M -36.58M -31.4M -26.88M -31.09M -15.12M -24.14M -22.05M
Depreciation & Amortization
n/a 456K 1.77M 2.06M 2.04M 2.03M 1.69M 2M 1.99M 2.06M 2.02M 1.92M 2.14M 1.49M 758K 663K 715K